In the intricate world of pharmaceutical synthesis, the availability of high-quality intermediates is paramount to the successful development and manufacturing of Active Pharmaceutical Ingredients (APIs). One such critical compound is (4-(Pyridin-2-Ylcarbamoyl)Phenyl)Boronic Acid, identified by its unique CAS number 850568-25-1. This versatile molecule serves as a vital building block in the synthesis of Acalabrutinib, a targeted therapy used in the treatment of certain B-cell malignancies.

Known by several synonyms, including [4-(2-Pyridylcarbamoyl)Phenyl]Boronic Acid and 4-(Pyridin-2-yl-Aminocarbonyl)Benzeneboronic Acid, this compound possesses a well-defined chemical structure represented by the Formula C12H11BN2O3 and a Molecular Weight of 242.04 g/mol. Its physical form is typically a white powder, suitable for handling and processing in pharmaceutical manufacturing environments. Key physical characteristics contribute to its utility in synthesis, including a reported melting point range of 124-128°C and a predicted density of approximately 1.33±0.1 g/cm3.

The primary significance of (4-(Pyridin-2-Ylcarbamoyl)Phenyl)Boronic Acid lies in its indispensable role as a pharmaceutical intermediate for Acalabrutinib. Acalabrutinib functions as a Bruton's tyrosine kinase (BTK) inhibitor, a targeted therapy that has shown considerable efficacy in treating chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The successful synthesis of Acalabrutinib at scale relies heavily on the consistent quality and availability of its precursors, with CAS 850568-25-1 being a key component in the synthetic route.

Achieving a high level of purity, typically specified at greater than 98%, is non-negotiable for pharmaceutical intermediates like (4-(Pyridin-2-Ylcarbamoyl)Phenyl)Boronic Acid. Impurities in intermediate stages can carry through to the final API, potentially affecting its efficacy, safety, and regulatory compliance. Therefore, rigorous quality control measures, including advanced analytical techniques, are essential throughout the manufacturing process to ensure that each batch meets stringent pharmaceutical standards. The 'Industrial Quality' classification suggests it is produced under conditions suitable for further processing in drug manufacturing, distinguishing it from laboratory-grade reagents intended solely for research.

The boronic acid functional group present in the molecule is particularly valuable in organic synthesis, frequently participating in cross-coupling reactions, such as Suzuki couplings, which are powerful tools for forming carbon-carbon bonds. This reactivity makes (4-(Pyridin-2-Ylcarbamoyl)Phenyl)Boronic Acid a versatile intermediate beyond just Acalabrutinib synthesis, potentially applicable in the creation of other complex organic molecules or pharmaceutical candidates, although its primary industrial demand stems from its role in Acalabrutinib production.

The global demand for oncology drugs continues to grow, driving the need for reliable and efficient supply chains for their constituent intermediates. Pharmaceutical companies and contract manufacturing organizations (CMOs) require consistent access to high-purity raw materials to maintain production schedules and meet market demand. Sourcing intermediates like CAS 850568-25-1 from established and reputable suppliers is crucial for ensuring continuity of supply and product quality.

Procuring pharmaceutical intermediates involves careful consideration of several factors beyond just the chemical specifications. Reliability, consistency of supply, technical support, and comprehensive documentation (such as Certificates of Analysis, technical data sheets, and regulatory support information) are all vital components of a successful supplier relationship. Companies looking to integrate this intermediate into their manufacturing process must evaluate potential partners based on their proven track record in synthesizing and supplying high-purity chemical raw materials for the pharmaceutical industry.

For those in the pharmaceutical sector seeking a dependable source for (4-(Pyridin-2-Ylcarbamoyl)Phenyl)Boronic Acid (CAS 850568-25-1), engaging directly with experienced chemical *manufacturer*s or specialized *supplier*s is the next step. Inquiring about the current *price*, available quantities, lead times, and shipping options is essential for planning procurement strategies. Companies have options to *buy* or *purchase* this critical Acalabrutinib intermediate in various quantities tailored to their specific production needs, from small research batches to large-scale industrial supply.

Detailed technical information, safety data, and quality certifications should be readily available from the supplier to facilitate the integration of CAS 850568-25-1 into existing synthetic processes and to meet regulatory requirements. Ensuring that the intermediate meets the specified purity (>98%) and physical characteristics (like its powder form) is key to successful downstream processing and ultimately, the quality of the final Acalabrutinib API. A strong partnership with a reliable supplier ensures a stable foundation for pharmaceutical manufacturing operations, supporting the continuous production of vital medications.